The introduction of novel insulin regimens and delivery devices has led to improved treatment of insulin-dependent diabetes mellitus (IDDM).7 In patients with exocrine insufficiency of the pancreas, improved pancreatic enzyme supplementation and antihypertensive medication have contributed markedly to improved quality of life.8 This evidence concerns the gene INS and type 1 diabetes mellitus.